Zealand Pharma A/S Price Chart
Zealand Pharma A/S 22ZA.F Financial and Trading Overview
| Zealand Pharma A/S stock price | 17.1 EUR |
| Previous Close | 17.1 EUR |
| Open | 17.1 EUR |
| Bid | 0 EUR x 0 |
| Ask | 0 EUR x 0 |
| Day's Range | 17.1 - 17.1 EUR |
| 52 Week Range | 9.2 - 27.4 EUR |
| Volume | 28 EUR |
| Avg. Volume | 2 EUR |
| Market Cap | 1.04B EUR |
| Beta (5Y Monthly) | 0.870881 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.122 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 240.78 EUR |
22ZA.F Valuation Measures
| Enterprise Value | 396.35M EUR |
| Trailing P/E | N/A |
| Forward P/E | -6.6279073 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 9.735154 |
| Price/Book (mrq) | 1.31498 |
| Enterprise Value/Revenue | 3.716 |
| Enterprise Value/EBITDA | -0.594 |
Trading Information
Zealand Pharma A/S Stock Price History
| Beta (5Y Monthly) | 0.870881 |
| 52-Week Change | -33.20% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 27.4 EUR |
| 52 Week Low | 9.2 EUR |
| 50-Day Moving Average | 17.17 EUR |
| 200-Day Moving Average | 14.42 EUR |
22ZA.F Share Statistics
| Avg. Volume (3 month) | 2 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 46.12M |
| Float | 39.63M |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 1.74% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -725.15% |
| Gross Margin | 119.08% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -30.42% |
| Return on Equity (ttm) | -153.90% |
Income Statement
| Revenue (ttm) | 106.66M EUR |
| Revenue Per Share (ttm) | 2.21 EUR |
| Quarterly Revenue Growth (yoy) | 24.39% |
| Gross Profit (ttm) | 103.99M EUR |
| EBITDA | -667036032 EUR |
| Net Income Avi to Common (ttm) | -1064203008 EUR |
| Diluted EPS (ttm) | -3.122 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1B EUR |
| Total Cash Per Share (mrq) | 19.34 EUR |
| Total Debt (mrq) | 512.55M EUR |
| Total Debt/Equity (mrq) | 76.13 EUR |
| Current Ratio (mrq) | 7.527 |
| Book Value Per Share (mrq) | 13.004 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -821875008 EUR |
| Levered Free Cash Flow (ttm) | -216960256 EUR |
Profile of Zealand Pharma A/S
| Country | Germany |
| State | N/A |
| City | Copenhagen |
| Address | Sydmarken 11 |
| ZIP | 2860 |
| Phone | 45 88 77 36 00 |
| Website | https://www.zealandpharma.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 220 |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Q&A For Zealand Pharma A/S Stock
What is a current 22ZA.F stock price?
Zealand Pharma A/S 22ZA.F stock price today per share is 17.1 EUR.
How to purchase Zealand Pharma A/S stock?
You can buy 22ZA.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Zealand Pharma A/S?
The stock symbol or ticker of Zealand Pharma A/S is 22ZA.F.
How many shares does Zealand Pharma A/S have in circulation?
The max supply of Zealand Pharma A/S shares is 60.72M.
What is Zealand Pharma A/S Price to Earnings Ratio (PE Ratio)?
Zealand Pharma A/S PE Ratio is now.
What was Zealand Pharma A/S earnings per share over the trailing 12 months (TTM)?
Zealand Pharma A/S EPS is -3.122 EUR over the trailing 12 months.